Skip to main content

Read an important notice regarding the data security incident McKesson reported on August 28, 2026. Read more.

Clinical Trials

BRCC Research Institute 2026

< All Clinical Trials

Zilovertamab Vedotin + SOC in participants with DLBCL

Disease Type: Lymphoma

A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003)

Locations

Alleghany , Blacksburg , Roanoke , Salem , Wytheville

View on ClinicalTrials.gov